Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Nimotuzumab Chemical Structure
BCP25910 Nimotuzumab 828933-51-3;780758-10-3
Nimotuzumab is a humanized monoclonal antibody and binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor).
Adecatumumab Chemical Structure
BCP29455 Adecatumumab 503605-66-1
Adecatumumab is a recombinant human IgG1 monoclonal antibody which is used to target tumor cells.
Ipilimumab Chemical Structure
BCP25419 Ipilimumab 477202-00-9
Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Aducanumab Chemical Structure
BCP24776 Aducanumab 1384260-65-4
Aducanumab targets aggregated forms of β-amyloid (Aβ) in the hopes of reducing its buildup.
Avelumab Chemical Structure
BCP25212 Avelumab 1537032-82-8
Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity.
Durvalumab Chemical Structure
BCP25841 Durvalumab 1428935-60-7
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules.
Pembrolizumab Chemical Structure
BCP24244 Pembrolizumab 1374853-91-4
Pembrolizumab (formerly MK-3475 and lambrolizumab) is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes.
Ramucirumab Chemical Structure
BCP29228 Ramucirumab 947687-13-0
Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors.It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2).
Eculizumab Chemical Structure
BCP26255 Eculizumab 219685-50-4
Eculizumab is a humanized monoclonal antibody functioning as a terminal complement inhibitor.
Eylea Chemical Structure
BCP29058 Eylea 845771-78-0
Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF).
123下一页末页共 34 条记录 1 / 4 页